[2-year experiences with a combination treatment of Parkinsonism with L-dopa and a decarboxylase inhibitor (Benserazid, Ro 4-4602)].
D001545:Benserazide / Q000627:therapeutic use; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors*; D002986:Clinical Trials as Topic; D012628:Dermatitis, Seborrheic / Q000188:drug therapy; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000627:therapeutic use*; D004338:Drug Combinations; D004341:Drug Evaluation; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D009069:Movement Disorders / Q000188:drug therapy; D009127:Muscle Rigidity / Q000188:drug therapy; D010300:Parkinson Disease / Q000188:drug therapy*; D013064:Speech Disorders / Q000188:drug therapy; D014202:Tremor / Q000188:drug therapy
D004338:Drug Combinations; D006834:Hydrazines; D004295:Dihydroxyphenylalanine; D001545:Benserazide; D002262:Carboxy-Lyases
Zweijährige Erfahrungen mit einer Kombinationsbehandlung des Parkinson-Syndroms mit L-Dopa und dem Dekarboxylasehemmer Benserazid (Ro 4-4602.